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Background: The metabolic syndrome (MS) might increase the risk of cardiovascular disease in testicular cancer (TC)
survivors. We investigated its prevalence, development, vascular implications, and the role of gonadal function.
Methods: TC survivors treated with chemotherapy and follow-up ≥3 years (N = 370, study I) were retrospectively
evaluated for the development of cardiovascular risk factors. A subgroup followed 3–20 years (N = 173, study II) was
compared with controls (N = 1085) for MS prevalence and evaluated for vascular function.
Results: In TC survivors (study I), 24% developed overweight, 24% hypercholesterolemia, and 30% hypertension, after
median follow-up of 1.7, 0.9, and 5.1 years, respectively. At the median follow-up of 5 years (study II), 25% of survivors
have the MS {odds ratio (OR) 2.2, [95% conﬁdence interval (CI) 1.5–3.3] compared with controls}. Survivors with MS
have features of inﬂammation and prothrombotic state, increased carotid artery intima-media thickness. Survivors with
testosterone levels <15 nmol/l (22%) have an increased risk of the MS (OR 4.1, 95% CI 1.8–9.3).
Conclusions: The current data suggest that the MS occurs at earlier age in TC survivors treated with chemotherapy
compared with controls and is accompanied by early signs of atherosclerosis. As low testosterone may have a causal
role, it is a target for interventions.
Key words: cancer survivors, cisplatin, hypogonadism, metabolic syndrome, testicular cancer, vascular damage
introduction
Cardiovascular disease (CVD) is a frequent late effect after
treatment of testicular cancer (TC) with an estimated 20-year
risk of about 18% in Dutch TC survivors [1]. Coronary heart
disease (CHD) is particularly common (estimated 20-year risk
10%) with approximately twofold increased risk of myocardial
infarctions in nonseminomatous TC survivors with attained
age <55 years [1]. Consequently, CVD represents a threat to
life expectancy and quality of life of a large proportion of
survivors. Both mediastinal radiotherapy [1] and platinum-
based chemotherapy regimens [1, 2] are associated with
increased CVD risk compared with treatment with surgery
alone. This increased CVD risk may be related to accelerated
atherosclerosis [3].
Platinum-based chemotherapy is associated with increased
prevalence of excessive weight gain [4], dyslipidemia [5],
hypertension [4, 5], and insulin resistance [5]. These factors
are the core components of the metabolic syndrome (MS),
which is associated with increased risk of atherosclerotic
disease in the general population [6]. Central obesity with
visceral adipose tissue deposition may have an important role.
Its hyperlipolytic state and excess of free fatty acids contribute
to insulin resistance. In addition, visceral adipose tissue
produces proinﬂammatory and prothrombotic factors [6, 7].
Although the MS may represent the connection between the
cancer treatment and the increased long-term CVD risk in
cancer survivors, information on its prevalence compared with
the general population, its etiology and development over time,
and its effects on vascular function and the eventual
development of overt CVD is scarce.
In this study, we present data on cardiovascular risk factors
and the MS in long-term (≥3 years) nonseminomatous TC
survivors treated with platinum-based chemotherapy: the
development over time of cardiovascular risk factors (study I),
the prevalence of MS compared with the general male
population, its associated features, and implications for
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Patients were selected from our cohort of long-term survivors of
disseminated nonseminomatous TC treated with platinum-based
chemotherapy at University Medical Center Groningen, between 1977 and
2004 (N = 439) (Figure 1). For the retrospective evaluation of the
development of cardiovascular risk factors (study I), patients had to have a
follow-up duration of ≥3 years. Patients with CHD [deﬁned as myocardial
infarction or coronary artery disease (proven by angiography, or by
treatment with angioplasty or bypass surgery)] before the start of
chemotherapy were excluded. The MS and its associated features (study II)
were cross-sectionally assessed in a subgroup of study I. Inclusion criteria
were attained age <60 years and follow-up of maximum 20 years. Exclusion
criteria were history of cardiac disease before or after chemotherapy,
radiotherapy to mediastinum, and participation in a previous study on
cardiovascular risk proﬁle [5]. The Ethics committee approved the study
and participants gave written informed consent.
control population
Control data concerning the MS in the general population were available
from two studies: men aged 28–60 years representing the general male
population in the Prevention of Renal and Vascular End-stage Disease
(PREVEND) study [8, 9] and, men aged 18–42 years participating as
sibling controls to a study on late effects in childhood cancer survivors
(CCS) [10]. Controls with a history of myocardial infarction or coronary
artery disease were excluded. The resulting control group existed of 1085
men (1020 from the PREVEND study and 65 from the CCS study) with
cross-sectional data available on waist circumference, blood pressure,
fasting lipid and glucose levels, and medication use, to allow for an
evaluation of the MS. The median age of the controls was 44 years (range
18–59).
evaluation of the development of cardiovascular
risk factors (study I)
Medical records, updated from general practitioners’ ﬁles, were evaluated
for disease- and treatment-related characteristics and follow-up data.
Cardiovascular risk factors were retrospectively evaluated for presence
prechemotherapy and development during follow-up. With respect to
overweight, body mass index [BMI; weight(kg)/height(m)2] >27.8 kg/m2
was recorded [11], and used in the early phase of establishment of the
cohort [5]. Hypertension was deﬁned as blood pressure systolic >150
mmHg and/or diastolic >95 mmHg [5, 12] and/or use of antihypertensive
drugs, and hypercholesterolemia as nonfasting cholesterol levels >6.5
mmol/l at ≥3 separate time points and/or use of cholesterol-lowering
drugs. Follow-up duration was calculated from the start of chemotherapy
to the last assessment of each risk factor and in case of overweight,
hypertension, or hypercholesterolemia also to date of this diagnosis.
assessment of the metabolic syndrome and its
associated features (study II)
Evaluation consisted of a medical history focused on medication use,
smoking, and family history for CVD (positive in case of parent or
brother/sister with CHD, cardiac death, or cerebrovascular accident at age
<60 years) and assessment of weight, height, waist circumference (at
umbilical level), hip circumference (at broadest part), and blood pressure.
Figure 1. Flow diagram of included patients.
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Blood pressure was measured at the outpatient clinic in a supine position
after a 10-min resting period.
Fasting blood samples were analyzed for HDL cholesterol and
triglycerides (plasma), glucose (plasma), and insulin (serum). Leptin and
adiponectin were determined by ELISA (#EZHL-80SK and #EZHADP-
61K, Linco Research, St Charles, MO, EDTA Plasma). In addition, markers
for inﬂammation, prothrombotic state, and endothelial activation were
determined. High-sensitivity C-reactive protein (hsCRP, serum),
ﬁbrinogen, Von Willebrand factor (vWF) antigen, plasminogen activator
type-1 (PAI-1) antigen, and tissue-type plasminogen activator (tPA)
antigen (citrate plasma) were measured as described previously [3]. Urinary
albumin excretion and creatinine clearance were determined from a 24-h
urine sample [3].
For assessment of the MS, the American Heart Association/National
Heart, Lung, and Blood Institute classiﬁcation [13] was used with the
presence of the MS in case of ≥3 of the following criteria: central obesity
(waist circumference ≥102 cm), high triglycerides (≥1.7 mmol/l or
medication), low HDL cholesterol (<1.03 mmol/l or medication), high
blood pressure (systolic ≥130 mmHg or diastolic ≥85 mmHg or
medication), and high glucose (≥5.6 mmol/l or medication). In addition, a
waist/hip ratio was calculated as measure for central obesity, HOMA-IR
index (fasting insulin (mU/l) × fasting glucose (mmol/l)/22.5) for insulin
resistance and a PAI-1/tPA ratio for prothrombotic state. Gonadal function
was analyzed by measuring serum total testosterone, luteinizing hormone,
and follicle-stimulating hormone.
As a measure of cardiovascular autonomic function, baroreﬂex
sensitivity (BRS) at rest in supine position was determined [14]. To assess
vascular structure and function, the intima-media thickness (IMT) of the
common carotid artery was measured, and carotid distensibility,
compliance, and stiffness calculated, as described previously [3].
statistical methods
The cumulative risk for cardiovascular risk factors in TC survivors (study I)
was plotted according to the Kaplan–Meier procedure. Presence of a risk
factor at last assessment was considered an event, with follow-up duration
calculated from the start of chemotherapy to the diagnosis of the risk
factor. When the risk factor was already present prechemotherapy, the
follow-up duration was set to zero. Median follow-up until development of
each risk factor was calculated for TC survivors in whom the risk factor
developed after completion of chemotherapy.
The risk of the MS and its components in TC survivors (study II) was
compared with the general population data by binary logistic regression
analysis with adjustment for age.
TC survivors with MS were compared with survivors without MS with
respect to associated features, vascular structure and function, and gonadal
function using the nonparametric Mann–Whitney U test for continuous
data and the χ2-test for categorical data. The association between MS and
markers for vascular damage was further analyzed using linear regression
analysis with MS as independent variable and adjustment for age. The
effect of gonadal function on the risk of the MS and its components was
tested with binary logistic regression analysis. Receiver-operator-
characteristic (ROC) curve analysis was used to estimate the optimal cutoff
value for total testosterone levels to differentiate between persons with and
without MS.
Statistical analyses were carried out with SPSS for Windows 16.0 (SPSS




The original cohort of 439 nonseminomatous TC patients
treated with platinum-based chemotherapy includes 370
patients without pretreatment history of CHD and with follow-
up ≥3 years (study I) (Figure 1). From the subgroup of 212
patients approached for participation in the study on the MS
(study II), 173 patients (82%) gave informed consent. Baseline
disease- and treatment-related characteristics and follow-up
data for the two study populations are shown in Table 1.
Table 1. Baseline characteristics and follow-up data of the TC patients in study I and the subpopulation included in study II
Study I (N = 370) Study II (N = 173)
Baseline characteristics
Age at start chemotherapy (years) Median (range) 28 (16–64) 28 (16–52)
Chemotherapy regimena
BEP/EP N (%) 262 (71%) 159 (92%)
PVB 27 (7%) 0 (0%)
PVB+ 42 (11%) 0 (0%)
PVB/BEP 15 (4%) 1 (1%)
Other 24 (7%) 13 (7%)
Follow-up data
Follow-up duration (years) Median (range) 12 (3–29) 5 (3–20)
Age at end follow-up (years) Median (range) 42 (19–73) 37 (19–59)
Deceased N (%) 25 (7%) not applicable
Death of testicular cancer 14 (4%) –
CHD N (%) 19 (5%) not applicable
Age at CHD (years) Median (range) 49 (30–62) –
Follow-up duration at CHD (years) Median (range) 15 (0–28) –
aCHD, coronary heart disease. Chemotherapy regimen: BEP, bleomycin, etoposide, cisplatin; EP, etoposide, cisplatin; PVB, cisplatin, vinblastin, bleomycin;
PVB+, PVB followed by maintenance therapy with cisplatin and vinblastin; PVB/BEP, alternating courses of PVB and BEP; Other, CEB (carboplatin,
etoposide, and bleomycin) or BOP/VIP (bleomycin, vincristin, cisplatin/etoposide, ifosfamide, and cisplatin).
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development of cardiovascular risk factors (study I)
Assessments of overweight, hypercholesterolemia, and
hypertension were available until a median follow-up of 9.1
years (range 0.2–28.9). At the last assessment, the prevalence of
risk factors was BMI >27.8 kg/m2 85/359 (24%, new in 15% of
the patients compared with prechemotherapy),
hypercholesterolemia 87/361 (24%, new in 14%), and
hypertension 106/359 (30%, new in 23%).
Figure 2 shows cumulative risks for the risk factors from the
start of chemotherapy. Median time for the development of
BMI >27.8 kg/m2 is 1.7 years (range 0.2–28.4), for
hypercholesterolemia 0.9 years (range 0.2–22.4), and for
hypertension 5.1 years (range 0.2–21.2).
the metabolic syndrome and associated features
(study II)
prevalence
At the median follow-up of 5 years (range 3–20) and attained
age of 37 years (range 19–59), the prevalence of the MS was
44/173 (25%). The prevalence increases with ascending age,
from 13.3% in survivors 18–30 years old to around 35% in
survivors 40–60 years old (Figure 3A). High blood pressure is
the most frequent component of the MS (59%), followed by
low HDL cholesterol (44%), high triglycerides (29%), central
obesity (17%), and high glucose levels (14%) (Figure 3B;
Table 2). All components tend to increase in prevalence
with age.
Adjusted for age, TC survivors show an increased risk of the
MS compared with the general population with an odds ratio
(OR) of 2.2 [95% conﬁdence interval (CI) 1.5–3.3] (Table 2).
This effect corresponds with 12.9 years’ increase in age
compared with the control population. TC survivors especially
have an increased risk of high blood pressure (Table 2).
metabolic syndrome associated features
There is no difference in smoking behavior and family history
for CVD between survivors with and without MS. Survivors
with MS have more central obesity, reﬂected by a higher waist/
hip ratio, higher plasma leptin and lower plasma adiponectin,
and increased HOMA-IR index (Table 3).
The association of MS with inﬂammation, prothrombotic
state, endothelial activation, and signs of vascular damage was
analyzed with adjustment for age. In presence of MS,
prothrombotic are increased (Supplemental Table S1, available
in Annals of Oncology online). The presence of MS is
associated with lower BRS and increased carotid artery IMT
Figure 2. Cumulative risk of cardiovascular risk factors overweight,
hypercholesterolemia, and hypertension from start of chemotherapy (study I).
Data are shown for patients in whom data on the concerned risk factors at
start of chemotherapy are available.
Figure 3. Prevalence of the metabolic syndrome in TC survivors and in
controls according to age category (A) and prevalence of its separate
components (B) (study II). *P < 0.05 compared with controls (χ2 test).
Table 2. Prevalence of and risk for the metabolic syndrome and its
separate components after chemotherapy for testicular cancer (study II,
N = 173). The risks are expressed as age-adjusted OR compared with the
control population with 95% CI and P value (binary logistic regression)
Dependent variables Prevalence OR 95% CI P
Metabolic syndrome 44/173 (25%) 2.2 1.5–3.3 0.0001
Separate components
High blood pressure 100/171 (59%) 2.5 1.8–3.6 <0.0001
Low HDL cholesterol 76/173 (44%) 1.7 1.2–2.3 0.003
High triglycerides 50/173 (29%) 1.2 0.8–1.7 0.424
Central obesity 29/170 (17%) 1.9 1.2–3.1 0.005
High glucose 24/170 (14%) 2.3 1.4–3.7 0.002
OR, odds ratios; 95% CI, 95% conﬁdence interval; HDL, high density
lipoprotein.
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(Supplemental Table S1, available in Annals of Oncology
online).
gonadal function
Median total testosterone level is lower in presence of MS
[excluding survivors with testosterone supplementation
(N = 9)] (Table 3; Supplemental Figure S1, available in Annals
of Oncology online). A cutoff value of total testosterone <15
nmol/l was considered best discriminating for the MS [area
under the ROC curve 0.65 (95% CI 0.55–0.74), area under the
ROC curve of age 0.65 (95% CI 0.55–0.75)]. Unsupplemented
total testosterone <15 nmol/l is associated with an age-adjusted
OR of 4.1 (95% CI 1.8–9.3; P = 0.001) for the MS
(Supplemental Table S2, available in Annals of Oncology
online). Low testosterone shows association with central
obesity [OR = 5.7 (95% CI 2.3–14.1); P < 0.001] and high
glucose levels [OR = 2.9 (95% CI 1.1–7.5); P = 0.031].
discussion
Our cross-sectional assessment of the MS (study II) shows that
at the median follow-up of 5 years, 25% of the TC survivors
have the MS. The syndrome shows an age-related increase in
prevalence up to around 35% for survivors aged 40–60 years. A
MS prevalence of 34% has recently been described after
chemotherapy in a Norwegian cohort of TC survivors with a
median age of 49 (range 31–69) years [15].
In this study, we show that the MS and its components
central obesity, low HDL cholesterol, high blood pressure and
high glucose levels are more prevalent in TC survivors than in
the general population. The risk of the MS in TC survivors is
2.2 (95% CI 1.5–3.3) times higher than in the general
population, corresponding with the risk of the MS in men aged
12.9 years. This suggests development of metabolic risk factors
at earlier age.
Although we did not have retrospective data on the MS for
our cohort of TC survivors, the regular assessment of
cardiovascular risk factors during standard follow-up enabled
us to evaluate the development over time of overweight,
hypertension, and hypercholesterolemia as surrogate markers
for the MS. Retrospective evaluation of the development of
cardiovascular risk factors (study I) shows that overweight and
hypercholesterolemia develop mainly within the ﬁrst 5 years
after platinum-based chemotherapy, after the median follow-
up of 1.7 years for BMI > 27.8 kg/m2 and 0.9 years for
hypercholesterolemia. The cumulative risks of overweight and
hypercholesterolemia show a plateau after a follow-up period
around 10 years. In contrast, hypertension develops later, after
the median follow-up of 5.1 years, and does not show a plateau
with prolonged follow-up. The later appearance of
hypertension may be related to its development secondary to
other metabolic risk factors. Moreover, hypertension may
reﬂect the long-term effect of direct chemotherapy-induced
endothelial damage.
Table 3. Comparison between TC survivors with the metabolic syndrome and TC survivors without the metabolic syndrome with respect to survivor
characteristics, cardiovascular risk factors, metabolic features, and gonadal function (study II)
Characteristicsa Metabolic syndrome present (44) Metabolic syndrome absent (129) Pb
Survivor characteristics and cardiovascular risk factors
Age at start chemotherapy (years) 29 (18–48) 26 (16–52) 0.086
Cumulative dose cisplatin (mg/m2) 421 (400–800) 406 (300–600) 0.22
Follow-up duration (years) 7 (3–20) 5 (3–20) 0.046
Age at study participation (years) 40 (23–57) 35 (19–59) 0.005
Smoking habits
Current smoker 14/44 (32%) 51/128 (40%) 0.546
Ex-smoker 11/44 (25%) 24/128 (19%)
Life-long nonsmoker 19/44 (43%) 53/128 (41%)
Positive family history CVD 6/42 (14%) 17/123 (14%) 1.000
Metabolic features
BMI (kg/m2) 28.4 (22.9–38.7) 24.0 (17.4–38.8) <0.0001
Waist/hip ratio 0.99 (0.83–1.12) 0.92 (0.80–1.15) <0.0001
Leptin (ng/ml) 12.77 (2.37–43.29) 3.71 (0.24–66.12) <0.0001
Adiponectin (μg/ml) 5.00 (2.04–11.19) 7.23 (2.76–17.40) <0.0001
HOMA-IR index 3.30 (1.56–23.86) 2.19 (0.20–2.04) <0.0001
Gonadal function
Testosterone supplementation 1/44 (2%) 8/129 (6%) 0.451
Total testosterone (nmol/l)c 15 (9–31) 18 (4–37) <0.0001
Testosterone <15 nmol/lc 19/43 (44%) 17/121 (14%) 0.0002
FSH (U/l)c 16.80 (4.34–47.50) 13.90 (2.38–7.50) 0.452
LH (U/l)c 6.42 (2.47–18.70) 5.45 (1.59–33.10) 0.190
CVD, cardiovascular disease.
aMedian (range) or n/N (%).
bMann–Whitney U test for continuous data and χ2 test for categorical data.
cFor TC survivors not receiving testosterone supplementation.
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A considerable proportion of the TC survivors with
overweight, hypercholesterolemia, or hypertension at the end
of follow-up already had these risk factors at the start of
chemotherapy. Unfortunately, it is unknown whether the
prechemotherapy prevalence of these factors is representative
for the age-matched general population because we do not
have retrospective data for the controls used in this study. On
the one hand, presence of cancer may contribute to lower
cholesterol levels and lower BMI as previously described [16].
On the other hand, the MS is increasingly recognized as risk
factors for the development of several cancer types [17] and
may be consequently overrepresented in patients with cancer.
Although we have no longitudinal data on the cardiovascular
risk factors in the general population, our data suggest that the
MS develops at earlier age in TC survivors (study II) and that
development of cardiovascular risk factors can already be
observed during the ﬁrst years of follow-up (study I).
In line with previous studies, we have found an association
between total testosterone levels and MS in TC survivors [18,
19]. In the general population, low testosterone levels are
predictive for the development of MS [20–22]. Our data show
that survivors with unsupplemented total testosterone <15
nmol/l (22% of the evaluated survivors) have an approximately
four times increased risk for the MS, particularly associated
with central obesity. We hypothesize that decrease in
testosterone levels and secondary central, visceral fat deposition
has an important role in the development of the MS.
Unsupplemented testosterone <15 nmol/l also shows an
association with high glucose levels. This corresponds with the
independent association of low to normal testosterone levels
with insulin resistance, as observed in older men [23].
TC survivors with MS show features of central, visceral fat
deposition: increased waist-to-hip ratio, elevated levels of
leptin, decreased levels of adiponectin, and insulin resistance.
Decreased adiponectin levels and increased ﬁbrinogen levels
are associated with an inﬂammatory state. Low-grade
inﬂammation and prothrombotic state are closely linked in the
pathobiology of atherosclerosis [24, 25]. The observed
association with increased carotid IMT and decreased BRS
underscores the potential clinical relevance of the MS in TC
survivors. Increase in IMT is an accepted marker of early
atherosclerosis [26] and decrease in BRS [27, 28] has also been
associated with atherosclerosis. Both are considered
unfavorable predictors for CVD.
Although our data suggest a role of the increased prevalence
of cardiovascular risk factors in the development of CVD in TC
survivors treated with platinum-based chemotherapy, prolonged
follow-up is needed to assess whether subclinical signs of
atherosclerosis eventually progress to overt CVD. The
homogeneity of the study population, most survivors having
been treated with the current standard regimen BEP, excludes
analysis of direct toxic effects of chemotherapy on the
vasculature. Cisplatin as well as bleomycin can induce
endothelial damage [29–31]. As cisplatin in plasma remains
detectable up to 20 years after chemotherapy [32] and may still
be partially in reactive form [33], we hypothesize that there is an
ongoing process of platinum-induced direct vascular toxicity.
The current observations on cardiovascular risk factors and
MS in long-term TC survivors suggest that detection and
timely treatment from the start of chemotherapy and during
the follow-up may contribute to a reduction in CVD risk.
Overweight and hypercholesterolemia can be detected mainly
within the ﬁrst 5 years after chemotherapy. However, the risk
for hypertension, which may also be a sign of developed
vascular damage, extends beyond a follow-up period of 10
years. Therefore, extended follow-up seems necessary.
By implementing prolonged follow-up, it will become clear
whether TC survivors with MS will have a higher CVD risk
than TC survivors without MS, than individuals with MS in
the general population. If previous treatment of TC turns out
to be an additional cardiovascular risk factor, treatment
indications for the MS may be more stringent for TC survivors.
In addition, a randomized, placebo-controlled trial may help to
evaluate whether testosterone supplementation contributes to
prevention or treatment of MS in TC survivors. In other cancer
survivors, i.e. after treatment of hematologic malignancies,
early breast cancer, and prostate cancer, there are also signs of
increased occurrence of the MS [34–38]. Although low
testosterone levels with androgen deprivation are likely to be
involved in the development of MS in prostate cancer
survivors, for survivors of hematological malignancies and
breast cancer, other mechanisms are involved. The more
general interventions should be considered in the later patients.
In conclusion, the MS is more prevalent and appears to
develop at earlier age in TC survivors treated with platinum-
based chemotherapy compared with the general population. It is
associated with subclinical, unfavorable changes in IMT and
BRS, which may precede overt CVD. The early development of
overweight and dyslipidemia advocates the development of
guidelines on detection and treatment from the start of
chemotherapy and during the follow-up. In addition, close
collaboration with primary care physicians seems necessary with
respect to extended follow-up and treatment of cardiovascular
risk factors. Low testosterone and its association with central
obesity appear to play a central role in the development of the
MS and is a target for future intervention studies.
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